The clinical study of plasma thrombin activatable fibrinolysis inhibitor in the patients with stroke

CUI Guiping,YANG Ping,HU Jingyi,WANG Ying,YAO Zhi
DOI: https://doi.org/10.3969/j.issn.1673-8640.2009.01.001
IF: 1.865
2009-01-01
Laboratory Medicine
Abstract:Objective To study the relation of thrombin activatable fibrinolysis inhibitor(TAFI) antigen(TAFI∶Ag) and its activity(TAFIa∶Ag) with stroke,and discuss the clinical significance of them in ischemic stroke(IS) and incerebral hemorrhage(ICH).Methods The plasma level changes of TAFI were measured in 228 stroke patients by enzyme-linked immunosorbent assay(ELISA).The levels of TAFI in IS and in ICH were compared respectively with in control.Results The levels of TAFI∶Ag and TAFIa∶Ag were significantly higher(P<0.01) in patients with IS([118.72±31.41] μg/mL,[168.79±55.36] ng/mL) and ICH([127.51±37.59]μg/mL,[207.99±73.71] ng/mL)as onset than in control([100.63±25.28]μg/mL,[126.43±31.88]ng/mL) and the incidence rate was higher.For evaluating the risk of stroke with TAFI,the odds rate(OR) for TAFIa∶Ag was about 3 times in IS compared with control,and was 7 times in ICH.Conclusions There is close relation between the plasma TAFI and stroke.The risk of stroke increases greatly along with higher TAFI.
What problem does this paper attempt to address?